Recent Updates
Recently added Catalysts
TYRA

Tyra Announces Pricing of Upsized Initial Public Offering Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and...

Key Takeaway: BofA Securities, Jefferies and Cowen are acting as joint book-running managers for the offering. Registration statements relating to the offering have been filed with the Securities and Exchange Commission and became effective on September 14, 2021. The offering will be made onl

Full Press Release Details

BofA Securities, Jefferies and Cowen are acting as joint book-running managers for the offering.
Registration statements relating to the offering have been filed with the Securities and Exchange Commission and became effective on September 14, 2021. The offering will be made only by means of a prospectus. When available, copies of the final prospectus may be obtained from BofA Securities, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, North Carolina 28255-0001, Attention: Prospectus Department, or by email at [email protected] ; from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by email at [email protected] or by telephone at 877-821-7388; or from Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (833) 297-2926, or by email at [email protected] .
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
Amy Conrad [email protected]
SOURCE Tyra Biosciences, Inc.

Related Links

21 %

Last updated: Sep 14, 2021